TAKESHI YAMAMOTOYA

Last Updated :2024/02/01

Affiliations, Positions
Graduate School of Biomedical and Health Sciences(Medicine), Assistant Professor
E-mail
ymmtyhiroshima-u.ac.jp

Basic Information

Major Professional Backgrounds

  • 2015/04/01, 2019/03/31, Hiroshima University, Graduate School of Biomedical and Health Sciences, Biomedical Chemistry, Assistant Professor
  • 2019/04/01, Hiroshima University, Graduate School of Biomedical & Health Sciences, Assistant Professor

Educational Backgrounds

  • The University of Tokyo, Graduate School of Medicine, PhD course, Internal Medicine, Japan, 2010/04, 2014/03
  • The University of Tokyo, Faculty of Medicine, Japan, 2004/04, 2008/03
  • The University of Tokyo, College of Arts and Sciences, Japan, 2002/04, 2004/03

Academic Degrees

  • The University of Tokyo

Educational Activity

  • [Bachelor Degree Program] School of Medicine : Program of Medicine : Medicine
  • [Master's Program] Graduate School of Biomedical and Health Sciences : Division of Integrated Health Sciences : Program of Biomedical Science
  • [Doctoral Program] Graduate School of Biomedical and Health Sciences : Division of Integrated Health Sciences : Program of Biomedical Science
  • [Doctoral Program] Graduate School of Biomedical and Health Sciences : Division of Biomedical Sciences : Program of Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Metabolomics

Research Keywords

  • Diabetes Mellitus
  • Glucose and Lipid Metabolism

Affiliated Academic Societies

  • The Japanese Society of Internal Medicine
  • The Japan Diabetes Society
  • The Molecular Biology Society of Japan

Educational Activity

Course in Charge

  1. 2023, Undergraduate Education, Year, Physiology and Biochemistry
  2. 2023, Undergraduate Education, 4Term, Clinicobiochemistry
  3. 2023, Graduate Education (Doctoral Program) , First Semester, Advanced Research on Biomedical Chemistry
  4. 2023, Graduate Education (Doctoral Program) , Second Semester, Advanced Research on Biomedical Chemistry

Research Activities

Academic Papers

  1. Par14 interacts with the androgen receptor, augmenting both its transcriptional activity and prostate cancer proliferation, CANCER MEDICINE, 12(7), 8464-8475, 202304
  2. Prolyl isomerase Pin1 promotes extracellular matrix production in hepatic stellate cells through regulating formation of the Smad3-TAZ complex, EXPERIMENTAL CELL RESEARCH, 425(2), 20230415
  3. Prolyl isomerase Pin1 binds to and stabilizes acetyl CoA carboxylase 1 protein, thereby supporting cancer cell proliferation, Oncotarget, 10(17), 1637-1648, 20190226
  4. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model, AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 309(1), G42-G51, 20150701
  5. Pin1 Inhibitor Juglone Exerts Anti-Oncogenic Effects on LNCaP and DU145 Cells despite the Patterns of Gene Regulation by Pin1 Differing between These Cell Lines., PLoS One PLoS One. 2015 Jun 3;10(6):e0127467, 10(6), e0127467, 20150603
  6. LUBAC Formation Is Impaired in the Livers of Mice with MCD-Dependent Nonalcoholic Steatohepatitis., Mediators of Inflammation, 2015(2015), 125380, 20150610
  7. Par14 protein associates with insulin receptor substrate 1 (IRS-1), thereby enhancing insulin-induced IRS-1 phosphorylation and metabolic actions., Journal of Biological Chemistry, 288(28), 20692-20701, 20130712
  8. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus, DIABETOLOGY & METABOLIC SYNDROME, 7, 20151119
  9. Role of uric acid metabolism-related inflammation in the pathogenesis of metabolic syndrome components such as atherosclerosis and non-alcoholic steatohepatitis., Mediators of Inflammation, 2016
  10. Physiological and Pathogenic Roles of Prolyl Isomerase Pin1 in Metabolic Regulations via Multiple Signal Transduction Pathway Modulations, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 17(9), 201609
  11. Reduced SHARPIN and LUBAC Formation May Contribute to CCl₄- or Acetaminophen-Induced Liver Cirrhosis in Mice., INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 18(2), 326, 20170404
  12. The prolyl isomerase Pin1 increases beta-cell proliferation and enhances insulin secretion, JOURNAL OF BIOLOGICAL CHEMISTRY, 292(28), 11886-11895, 20170714
  13. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 18(8), 201708
  14. Ggastrointestinal symptom prevalence depends on disease duration and gastrointestinal region in type 2 diabetes mellitus, WORLD JOURNAL OF GASTROENTEROLOGY, 23(36), 6694-6704, 20170928
  15. ★, Trk-fused gene (TFG) regulates pancreatic beta cell mass and insulin secretory activity, SCIENTIFIC REPORTS, 7, 20171012
  16. Gut Microbiota as a Therapeutic Target for Metabolic Disorders, CURRENT MEDICINAL CHEMISTRY, 25(9), 984-1001, 2018
  17. Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 19(10), 201810
  18. The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its Anti-Inflammatory and Anti-Fibrotic Effects in the gddY Mouse Model, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 19(12), 201812
  19. Prolyl Isomerase Pin1 Suppresses Thermogenic Programs in Adipocytes by Promoting Degradation of Transcriptional Co-activator PRDM16, CELL REPORTS, 26(12), 3221-+, 20190319
  20. Protective Effect of Sex Hormone-Binding Globulin against Metabolic Syndrome: In Vitro Evidence Showing Anti-Inflammatory and Lipolytic Effects on Adipocyt es and Macrophages, MEDIATORS OF INFLAMMATION, 2018
  21. Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice, DIABETOLOGY & METABOLIC SYNDROME, 11, 20190722
  22. Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 20(19), 201910
  23. Pin1 Plays Essential Roles in NASH Development by Modulating Multiple Target Proteins, CELLS, 8(12), 201912
  24. Prolyl isomerase Pin1 in metabolic reprogramming of cancer cells, CANCER LETTERS, 470, 106-114, 2020
  25. Development of Pin1 Inhibitors and their Potential as Therapeutic Agents, CURRENT MEDICINAL CHEMISTRY, 27(20), 3314-3329, 2020
  26. Prolyl isomerase Pin1 interacts with adipose triglyceride lipase and negatively controls both its expression and lipolysis, METABOLISM-CLINICAL AND EXPERIMENTAL, 115, 202102
  27. Carnosic Acid and Carnosol Activate AMPK, Suppress Expressions of Gluconeogenic and Lipogenic Genes, and Inhibit Proliferation of HepG2 Cells, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 22(8), 202104
  28. Pathological Role of Pin1 in the Development of DSS-Induced Colitis, CELLS, 10(5), 202105
  29. Impact of Plasma Xanthine Oxidoreductase Activity on the Mechanisms of Distal Symmetric Polyneuropathy Development in Patients with Type 2 Diabetes, BIOMEDICINES, 9(8), 202108
  30. ★, Prolyl isomerase Pin1 plays an essential role in SARS-CoV-2 proliferation, indicating its possibility as a novel therapeutic target, SCIENTIFIC REPORTS, 11(1), 20210917
  31. ★, Involvement of neuronal and muscular Trk-fused gene (TFG) defects in the development of neurodegenerative diseases, SCIENTIFIC REPORTS, 12(1), 20220204

Publications such as books

  1. 2016/01, medicina Vol.53 No.1, The action mechanism of SGLT2 inhibitors., 2016, 1, Others, Joint work, Takeshi Yamamotoya, Yusuke Nakatsu, Tomoichiro Asano
  2. 2016/02, Anti-aging Medicine, SGLT2 inhibitors - their potential beyond glucose-lowering, 2016, 2, Others, Joint work, Takeshi Yamamotoya, Yusuke Nakatsu, Tomoichiro Asano
  3. 2017/02, Diabetes Strategy Vol.7 no.1 2017 Winter, 2017, 2, Others, Joint work

Invited Lecture, Oral Presentation, Poster Presentation

  1. The role of Trk-fused gene (TFG) in pancreatic beta cells, 2016/12/02, Without Invitation, Japanese
  2. The role of adipocyte Trk-fused gene (TFG) in metabolin regulation, 2018/11/30, Without Invitation, Japanese
  3. Pin1 and Trk-fused gene (TFG): novel regulators for beta-cell mass and function, Takeshi Yamamotoya, Yusuke Nakatsu, Akifumi Kushiyama, Hisamitsu Ishihara, Tomoichiro Asano, 2019/05/24, With Invitation, English

External Funds

Acceptance Results of Competitive Funds

  1. 2023/01/01, 2024/12/31
  2. KAKENHI(Grant-in-Aid for Scientific Research (C)), 2021, 2023
  3. 2020, 2022
  4. Grants-in-Aid for Scientific Research, Elucidation of the mechanisms how Trk-fused gene (TFG) regulates glucose and lipid metabolism in pancreas, liver and adipose tissue., 2015, 2017
  5. Novartis Pharma Research Grants 2016, Elucidation of the roles of Trk-fused gene (TFG), a causative gene of hereditary morot and sensory neuropathy with proximal-predominant muscle weakness (HMSN-P), on glucose and lipid metabolism and neurological function., 2016, 2017
  6. 2016, 2017
  7. 2017, 2018
  8. KAKENHI(Grant-in-Aid for Young Scientists (B)), 2017, 2019
  9. KAKENHI(Grant-in-Aid for Early-Career Scientists), 2019, 2020